Cabergamone 0.5 mg 2 tablets

Trade name:

Cabergamone

Composition

Each tablet contains:

Cabergoline 0.5 mg

Auxiliary components:

Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, talc, magnesium stearate.

Properties

Derivative of ergot alkaloid ergoline, dopamine D2 receptor agonist. By stimulating these receptors of the pituitary gland, it causes a pronounced and prolonged inhibition of the secretion of the hormone of the anterior lobe prolactin. It has a therapeutic effect in hyperprolactinemia, reducing the severity of such manifestations as menstrual irregularities (oligomenorrhea, amenorrhea), infertility, galactorrhea; impotence, decreased libido. Prevents and suppresses physiological lactation.

At doses higher than those required to suppress prolactin secretion, cabergoline produces a central dopaminergic effect due to the stimulation of dopamine D2 receptors. The action is dose-dependent. Cabergoline reduces daily movement fluctuation in patients with Parkinson’s disease who are treated with a levodopa / carbidopa combination. Cabergoline has selective activity without affecting the basal secretion of other pituitary hormones and cortisol.

The pharmacodynamic effects of cabergoline, which are not associated with therapeutic activity, include only a decrease in blood pressure. With a single dose, the maximum hypotensive effect is observed during the first 6 hours and is dose-dependent.

Indications

Prevention of physiological lactation after childbirth; suppression of already established postpartum lactation; treatment of disorders associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation, galactorrhea; prolactin-secreting pituitary adenomas (micro- and macroprolactinomas idiopathic hyperprolactinemia; syndrome of «empty» Turkish saddle in combination with hyperprolactinemia.

Method of administration and dosage:

It is taken orally with food.

Contraindications

Hypersensitivity to cabergoline and ergot alkaloids; dysfunctions of the heart and respiration due to fibrotic changes in the lungs, pericardium, heart valves or retroperitoneal space, or the presence of such conditions in history; with long-term therapy — anatomical signs of the pathology of the valve apparatus of the heart (such as thickening of the valve leaflet, narrowing of the valve lumen, mixed pathology, narrowing and stenosis of the valve), confirmed by echocardiography performed at the beginning of therapy; risk of postpartum psychosis; period of breastfeeding; children under 16 years old.

With care: arterial hypertension that developed during pregnancy, for example, preeclampsia or postpartum arterial hypertension; severe cardiovascular disease, Raynaud’s syndrome; hypotension, Parkinson’s disease; severe psychotic or cognitive impairment (including a history); peptic ulcer, gastrointestinal bleeding; severe hepatic impairment (lower doses are recommended renal failure; simultaneous use with drugs that have an antihypertensive effect (due to the risk of orthostatic hypotension).

Precautions:

Side effects

From the side of the cardiovascular system: palpitations, angina pectoris; with prolonged use, cabergoline usually has a hypotensive effect, in some cases orthostatic arterial hypotension may occur; possible asymptomatic decrease in blood pressure during the first 3-4 days after childbirth.

From the nervous system: dizziness / vertig tremor, headache, increased fatigue,

drowsiness, depression, asthenia, paresthesia, fainting, nervousness, anxiety, insomnia, impaired concentration, impaired impulse control (excessive passion for shopping, overeating, spending money ).